Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

被引：102

作者：

Araki, Manabu ^{[1
]}

Aranami, Toshimasa ^{[2
]}

Matsuoka, Takako ^{[2
]}

Nakamura, Masakazu ^{[2
]}

Miyake, Sachiko ^{[2
]}

Yamamura, Takashi ^{[1
,2
]}

机构：

[1] Natl Ctr Hosp, Multiple Sclerosis Ctr, Natl Ctr Neurol & Psychiat, Kodaira, Tokyo 1878551, Japan

[2] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Immunol, Kodaira, Tokyo 1878502, Japan

来源：

MODERN RHEUMATOLOGY | 2013年 / 23卷 / 04期

关键词：

Interleukin-6; Neuromyelitis optica; Plasmablast; Tocilizumab; MULTIPLE-SCLEROSIS; MECHANISMS; LESIONS; MARKER;

D O I：

10.1007/s10165-012-0715-9

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthly administration of the anti-IL-6 receptor antibody tocilizumab. The treatment rapidly reduced the elevated numbers of plasmablasts and anti-AQP4 autoantibodies in the patient. Furthermore, neuropathic pain and disability scores gradually improved. Tocilizumab may be considered as a therapeutic option for NMO.

引用

收藏

页码：827 / 831

页数：5

相关论文

共 18 条

[1]

Neuromyelitis Optica: Pathogenicity of Patient Immunoglobulin In Vivo [J].

Bradl, Monika ;

Misu, Tatsuro ;

Takahashi, Toshiyuki ;

Watanabe, Mitsutoshi ;

Mader, Simone ;

Reindl, Markus ;

Adzemovic, Milena ;

Bauer, Jan ;

Berger, Thomas ;

Fujhara, Kazuo ;

Itoyama, Yasuto ;

Lassmann, Hans .

ANNALS OF NEUROLOGY, 2009, 66 (05) :630-643

[2]

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica [J].

Chihara, Norio ;

Aranami, Toshimasa ;

Sato, Wakiro ;

Miyazaki, Yusei ;

Miyake, Sachiko ;

Okamoto, Tomoko ;

Ogawa, Masafumi ;

Toda, Tatsushi ;

Yamamura, Takashi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) :3701-3706

[3]

An open label study of the effects of rituximab in neuromyelitis optica [J].

Cree, BAC ;

Lamb, S ;

Morgan, K ;

Chen, A ;

Waubant, E ;

Genain, C .

NEUROLOGY, 2005, 64 (07) :1270-1272

[4]

Imura T, 2008, J LUMBER SPINE DISOR, V14, P134

[5]

Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica [J].

Kleiter, Ingo ;

Hellwig, Kerstin ;

Berthele, Achim ;

Kuempfel, Tania ;

Linker, Ralf A. ;

Hartung, Hans-Peter ;

Paul, Friedemann ;

Aktas, Orhan .

ARCHIVES OF NEUROLOGY, 2012, 69 (02) :239-245

[6]

KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444

[7]

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis [J].

Lennon, VA ;

Wingerchuk, DM ;

Kryzer, TJ ;

Pittock, SJ ;

Lucchinetti, CF ;

Fujihara, K ;

Nakashima, I ;

Weinshenker, BG .

LANCET, 2004, 364 (9451) :2106-2112

[8]

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel [J].

Lennon, VA ;

Kryzer, TJ ;

Pittock, SJ ;

Verkman, AS ;

Hinson, SR .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) :473-477

[9]

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica [J].

Lucchinetti, CF ;

Mandler, RN ;

McGavern, D ;

Bruck, W ;

Gleich, G ;

Ransohoff, RM ;

Trebst, C ;

Weinshenker, B ;

Wingerchuk, D ;

Parisi, JE ;

Lassmann, H .

BRAIN, 2002, 125 :1450-1461

[10]

McCaffery M., 1993, PAIN CLIN MANUAL NUR